Table 1.
Stimulation of cAMP Accumulation by D1R Agonistsa
| compound | EC50 (nM) | Emax (% of DA) |
|---|---|---|
| dopamine | 3.2 ± 2 | 100 |
| A77636 | 1.6 ± 0.3 | 98.3 ± 8.5 |
| dihydrexidine | 1.5 ± 0.5 | 92.9 ± 1 |
| apomorphine | 0.45 ± 0.1 | 76.2 ± 8.9 |
| SKF81297 | 2.0 ± 0.2 | 99.9 ± 2.9 |
| chloro-APB | 0.73 ± 0.1 | 87.9 ± 5 |
| SKF83822 | 0.12 ± 0.06 | 73.9 ± 5.9 |
| fenoldopam | 2.8 ± 0.1 | 91.8 ± 3.8 |
| SKF38393 | 1.1 ± 0.4 | 86.7 ± 9.3 |
| SKF83959 | 0.2 ± 0.02 | 59.6 ± 11 |
| SKF82957 | 0.3 ± 0.09 | 60.2 ± 4.5 |
| SKF77434 | 1.0 ± 0.3 | 51.9 ± 3.8 |
| SKF75670 | 0.45 ± 0.03 | 30 ± 3.7 |
a
EC50 and Emax values were obtained from nonlinear regression analysis of individual dose–response curves as shown in Figure 2. Comparison to the control maximal response exhibited by dopamine (DA) derives the percent response (Emax) of a test compound.